/ August 2017 ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Thursday, 31 August 2017

NTPC was the most active stock in terms of value and volume on NSE during the afternoon hours on Thursday. The stock was trading almost flat at Rs 167.9 per share, marginally down by 0.03%.In two blocks deals, 16.1 lakh shares of the company were traded at Rs 164-164.50 per share on NSE during early hours of Thursday.

NTPC has attracted a total traded volume of 5,82,57,139 shares and traded value of Rs 967.59 crore as of 1226 hours on Thursday. The stock has lost around 5% in the past three trading sessions. It was the top loser on the BSE Power index. BSE Power index was trading at 2,250 level, marginally up by 0.26%.
 
The government has raised around Rs 9,000 crore through the share sale in the company. The government currently owns 69.74% stake in NTPC. Post the OFS, the shareholding of government would come down to 63.1%.Meanwhile, Nifty was trading marginally higher by 4 points at 9,888 level, while Sensex was trading at 31,650 level, up by 3 points.

For mail us here: info@ways2capital.com

✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

The stock of Fortis Healthcare was facing the heat during Thursday’s trading session as the Supreme Court (SC) refused any relief to the company's promoters and their banks who are trying to sell some of the pledged promoter holdings. The stock plunged over 5% on the BSE.
 
The apex court, maintaining the status quo, clarified that promoters Singh brothers cannot sell both encumbered and non-encumbered assets. The court also refused permission to banks seeking to sell pledged shares, reported a leading business daily.

Fortis Healthcare was trading at Rs 148 per share, down by Rs 6.30 or 4.08% as at 1212 hours on Thursday, on the BSE. The stock hit an intraday high and low of Rs 156.95 and Rs 145.35, respectively.

The stock attracted a traded volume of 1,20,07,798 shares and traded value of Rs 17,996.09 lakh on the NSE. The company had hit its 52-week high of Rs 228.95 on May 3, 2017, and 52-week low of Rs 125.55 on August 22, 2017, on the NSE.
 
For mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
The shares of RPP Infra Projects soared by nearly 2% during Thursday’s trading session after the company  announced that it has bagged an order valued Rs 38.9 crore.The order was received from Sumitomo Electric Industries Limited for setting up +/- 320KV, 2x1000MW VSC base HVDC Terminals and DC XLPE Cable system between Pugalur and North Trichur associated with HVDC Bipole link between western region (Raigarah, Chhattisgarh) and Southern region (Pugalur, Tamil Nadu and North Trichur, Kerala)

Construction of concrete duct bank and supply of all necessary items including HDPE pipes for 13.50 Km from Vadakkancherry for worth of Rs 389 million. The said order is expected to be completed within 18 Months.

The stock was trading up by 1.75% at Rs 267 per share on BSE at 1148 hours. It opened at Rs 264.50 per share. It touched its intraday high and low at Rs 269.20 and Rs 260 per share, respectively. The stock has attracted a total traded volume of 1,01,453 shares and traded value of Rs 269.66 lakh on NSE at 1155 hours.

The stock’s 52-week high stood at Rs 362.75 per share as on February 10, 2017 and 52-low was at Rs 147.35 as on November 9, 2016. 

 
For mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Hero MotoCorp has overtaken Bajaj Auto in terms of market capitalisation on BSE. Hero now becomes second most valued automobile company on BSE after Eicher Motors. Eicher Motors’ market capitalisation stood at Rs 84,318.31 crore as per the closing price of Rs 30,973.7 per share on Wednesday. Bajaj Auto’s market capitalisation stood at Rs 79,487.67 crore as per the closing price of Rs 2,746.95 per share in the previous trading session.

Bajaj Auto was trading down by 0.42% as of 1031 hours at Rs 2,739.05 per share, while Hero MotoCorp was trading at Rs 4,012 per share, up by 0.3% on BSE. As per the last traded price of the stocks on BSE, the market capitalisation of Hero MotoCorp stands at Rs 80,118.03 crore, higher by Rs 858 crore as compared to the market capitalisation of Bajaj Auto which stands at Rs 79,259.07 crore.


Other automobile stocks have been trading in the negative territory as auto companies expect a fall in demand after the Cabinet approved an ordinance that will allow the cess on luxury cars and sports utility vehicles to be raised to as much as 25%. Meanwhile, Nifty was trading at 9,867.8 level, down by 16 points while Sensex was trading at 31,582 level, down by 64 points.
For mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Pharma major, Ajanta Pharma, announced that the company has launched Eletriptan Hydrobromide Tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc. The product was launched in two strengths, 20 mg and 40 mg tablets. The drug is a bioequivalent generic version of Relpax 1 Tablets. It is used to treat migraines. Meanwhile, the stock was trading up by 0.37% at Rs 1,197 per share on BSE at 1105 hours. The stock attracted a total traded volume of 2,09,575 shares and traded value of Rs 2,534.31 lakh on NSE at 1107 hours.


The drug is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, the company has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, 2 tentative approvals, and 14 ANDAs under review with US FDA. So far it has launched 14 products in the US market. The company’s consolidated revenue for the Q1FY18 remained flat at Rs 473 crore as against Rs 476 crore in corresponding quarter of last year. The PAT for the quarter came in at Rs 94.8 crore, yoy decline of 20.7%.
 For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
The shares of Ujjivan Financial Services jumped by over 3% intraday on Thursday’s trading session on the back of the reports that CDC group has offloaded a part of its stake in Ujjivan. The shares were bought by Cinnamon Capital. According to the bulk deal data available with NSE, CDC Group sold 59 lakh shares, amounting to 4.93% stake of Ujjivan Financial Services for around Rs 212 crore, via an open market transaction.


The stock was trading higher by 2.36% at Rs 366 per share on BSE at 0948 hours. It opened at Rs 365 per share.It touched its intraday high and low at Rs 372 and Rs 361 per share, respectively. The stock witnessed a spurt in volume by more than 1.12 times on Thursday. The stock attracted a total traded volume by 32,11,993 shares and traded value of Rs 11,811.14 lakh on NSE at 0946 hours.

The stock’s 52-week high was at Rs 484.90 as on October 04,2016 and low was at Rs 284.85 as on December 26, 2016.Ujjivan Financial Services, formerly Ujjivan Financial Services Private Limited, is a non-banking finance company engaged in the micro finance lending business.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Wednesday, 30 August 2017


The shares of Bombay Dyeing and Manufacturing Company jumped by over 13% intraday as the stock witnessed a spurt in volume by more than 2.94 times during Wednesday’s trading session.

The stock was trading higher by 13.78% at Rs 106 per share on BSE at 1415 hours. It opened at Rs 95 per share. The stock touched its new 52-week high at Rs 106.90 per share on Wednesday. The stock attracted a total traded volume of 1,89,59,458 shares and traded value of Rs 19,131.99 lakh on NSE at 1419 hours.

The company’s standalone revenue for the Q1FY18 came in at Rs 622.9 crore, registering 30.8% yoy increase. This was primarily driven by 137% yoy increase in revenues from real estate segment. The company’s net loss narrowed to Rs 32.7 crore vs Rs 43.6 crore in Q1FY17.


For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Pharma major, Aurobindo Pharma is in talks to buy the Russia business of Shreya Life Sciences (SLPL) in a deal potentially valued between USD 80 to 100 million (Rs 511 to 638.8 crore), according to a leading news agency.

The company has given a term sheet and talks currently hinge on the final valuation. Mumbai-based SLPL is keen to retain a part of the business and may decide against selling everything.

SLPL has presence in therapeutic segments such as cardiology, diabetology, anti-microbials, anti-tuberculosis, anti-osteoporotics, anti-malarials, gastrointestinals, pain management, gynaecology, paediatric care, infertility management and diabetes care. The company has a product portfolio comprising more than 200 products across various therapeutic segments.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Bharat Road Network Limited (BRNL) initial public offering (IPO) is going to open for subscription on Wednesday, September 6, 2017, and shall close on Friday, September 08, 2017. The company has fixed the price band at Rs 195 to Rs 205 per share.

The company has recently received the approval from Registrar of Companies (RoC), West Bengal on August 23, 2017, in regard to the Red Herring Prospectus filed.

The public issue consists of up to 29,300,000 equity shares of face value of Rs 10 each of BRNL. The equity shares will have a face value of Rs 10 and the final price band will be decided in consultation with the Book Running Lead Managers (BRLMs).

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Cement sector player, Visaka Industries soared 10.34% at Rs 681.00 per share on BSE at 1405 hours. The stock traded at a fresh 52-week high value of 699.00 per share on BSE. The stock on NSE attracted a total traded volume of 10,79,934 shares and a traded value of Rs 7,276.92 lakhs.

The company has been maintaining a dividend payout ratio of 29.38%. The company had a growth of 5.20% over the past five years. The company has a return on equity of 8.40% for the last three years. On yearly basis, the stock has given 276.77% returns and has outperformed BSE Small-cap index and BSE 500 index.

Earlier on Monday, the company launched a new product named as ATUM, which is an eco-friendly, energy efficient and energy generating roofing product.

Visaka Industries is engaged in the manufacture and sale of cement asbestos sheets, fiber cement sheets (V-Boards), panels and spinning (Synthetic Spun Yarn). The company offers products, including cement asbestos products, fibre cement flat board products and textiles.

Meanwhile, BSE Sensex gained 299 points or 0.95% at 31,687 level and Nifty gained 99 points or 1.02% at 9,895 level.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Tata Elxsi and V-Nova, a leading provider of video compression solutions, announced a partnership that enables operators to deploy V-Nova PERSEUS technology at an accelerated pace, the company said in a filing to the bourses on Wednesday.

Tata Elxsi, a leading provider of specialised broadcast and communications engineering services, has already integrated V-Nova’s award-winning technology within the set-top-box (STB) of a satellite TV operator in Europe, enabling rapid deployment and immediate benefits, said the company.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 




The stock of Kalpataru Power Transmission was on a roll during Wednesday’s trade as it soared over 12% on the BSE. The stock traded on a new 52-week high value of Rs 404.45 per share.

Kalpataru Power Transmission was trading at Rs 387.55 per share, up by Rs 39.60 or 11.38% as at 1050 hours on Wednesday, on the BSE as against its previous close of Rs 347.95. The stock witnessed a spurt in volume by more than 12.39.

The stock attracted a traded volume of 10,63,584 shares and traded value of Rs 4,152.98 lakh on the NSE. The company hit its 52-week high of Rs 404.60 on Wednesday, 30 August 2017, and had hit its 52-week low of Rs 207 on November 9, 2016, on the NSE.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

Zydus Cadila has received the final approval from the USFDA to market Aspirin and extended-release Dipyridamole capsules in the strength of 25mg/200 mg. The drug is an antiplatelet agent which works in the prevention of excessive blood clotting and is used to reduce the risk of stroke in patients who have or had or are at the risk of having a stroke.

The drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad. The sales of Aspirin and extended-release Dipyridamole capsules are estimated at USD 198.7 million.

The group has more than 140 approvals and has so far filed over 300 ANDA’s since the commencement of the filing process in FY 2003-04.

Meanwhile, the stock of Cadila Healthcare gained 2.44% at Rs 510.05 per share on BSE at 1055 hours. The stock on NSE attracted a total traded volume of 6,56,721 shares and a traded value of Rs 3,342.25 lakh.

The stock on yearly basis has given 31.42% returns and has outperformed BSE Sensex index and BSE Healthcare index. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717